Display options
Cite
van Eenige R, Ying Z, Tambyrajah L, et al. Cannabinoid type 1 receptor inverse agonism attenuates dyslipidemia and atherosclerosis in APOE∗3-Leiden.CETP mice. J Lipid Res. 2021;62:100070doi: 10.1016/j.jlr.2021.100070.
van Eenige, R., Ying, Z., Tambyrajah, L., Pronk, A. C. M., Blomberg, N., Giera, M., Wang, Y., Coskun, T., van der Stelt, M., Rensen, P. C. N., & Kooijman, S. (2021). Cannabinoid type 1 receptor inverse agonism attenuates dyslipidemia and atherosclerosis in APOE∗3-Leiden.CETP mice. Journal of lipid research, 62100070. https://doi.org/10.1016/j.jlr.2021.100070
van Eenige, Robin, et al. "Cannabinoid type 1 receptor inverse agonism attenuates dyslipidemia and atherosclerosis in APOE∗3-Leiden.CETP mice." Journal of lipid research vol. 62 (2021): 100070. doi: https://doi.org/10.1016/j.jlr.2021.100070
van Eenige R, Ying Z, Tambyrajah L, Pronk ACM, Blomberg N, Giera M, Wang Y, Coskun T, van der Stelt M, Rensen PCN, Kooijman S. Cannabinoid type 1 receptor inverse agonism attenuates dyslipidemia and atherosclerosis in APOE∗3-Leiden.CETP mice. J Lipid Res. 2021;62:100070. doi: 10.1016/j.jlr.2021.100070. Epub 2021 Mar 23. PMID: 33766515; PMCID: PMC8082266.
Copy Download .nbib Format: NLM
Share it on

J Lipid Res. 2021;62:100070. doi: 10.1016/j.jlr.2021.100070. Epub 2021 Mar 23.

Cannabinoid type 1 receptor inverse agonism attenuates dyslipidemia and atherosclerosis in APOE∗3-Leiden.CETP mice.

Journal of lipid research

Robin van Eenige, Zhixiong Ying, Lauren Tambyrajah, Amanda C M Pronk, Niek Blomberg, Martin Giera, Yanan Wang, Tamer Coskun, Mario van der Stelt, Patrick C N Rensen, Sander Kooijman

Affiliations

  1. Department of Medicine, Division of Endocrinology, and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.
  2. Center for Proteomics & Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
  3. Department of Medicine, Division of Endocrinology, and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands; Center for Immunological and Metabolic Diseases, MED-X institute, and Department of Endocrinology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  4. Department of Diabetes/Endocrine, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA.
  5. Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands.
  6. Department of Medicine, Division of Endocrinology, and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands; Center for Immunological and Metabolic Diseases, MED-X institute, and Department of Endocrinology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address: [email protected].

PMID: 33766515 PMCID: PMC8082266 DOI: 10.1016/j.jlr.2021.100070

Abstract

Pharmacological blockade of the cannabinoid type 1 receptor, a G protein-coupled receptor expressed in the central nervous system and various peripheral tissues, reverses diet-induced obesity and dyslipidemia through the reduction of food intake and altered nutrient partitioning. This strategy is being explored for a number of therapeutic applications; however, its potency for the treatment of atherosclerotic cardiovascular disease via improvements in lipid metabolism remains unclear. Therefore, here, we aimed to investigate whether inhibition of the endocannabinoid system can attenuate atherosclerosis development through improvement of dyslipidemia. Lean, dyslipidemic female APOE∗3-Leiden.CETP transgenic mice were fed a Western-type diet supplemented with or without the cannabinoid type 1 receptor inverse agonist rimonabant (20 mg·kg body weight

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Keywords: adipose tissue; atherosclerosis; bile acids and salts/metabolism; cannabinoid receptor type 1; cardiovascular disease; drug therapy; endocannabinoids; lipids; lipoproteins/metabolism

Conflict of interest statement

Conflict of interest T. C. is an employee and shareholder of Eli Lilly and Company. Eli Lilly and Company had no role in study design, data collection and analysis, decision to publish, or preparation

Publication Types